ArticleOphthalmology and therapy2025

Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration.

Federico Beretta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.